Avail Nexus upgrade is awesome 🤝Avail (@AvailProject):Imagine using Aave to bring in assets from 11 chains... without EVER leaving the app.That's the Avail Nexus upgrade. No bridges. No wallets. No manual swaps.Just seamless cross-chain liquidity.Watch it live 👀 https://t.co/QT9sbelnKO ...

子行业周度核心观点： 光伏&储能：新能源为代表的新兴制造业是本轮"反内卷"的核心聚焦领域，光伏则是核心领域中的标杆示范行业， 当前"依法依规"进行干预的价格端已初显成效，继续关注终端价格传导能力、产业链对涨价趋势一致预期的形成、 以及供给侧自上而下的潜在动作；此外，继续重申推荐受益于美国政策不确定性消除、国内新能源全面市场化+反内 卷驱动格局改善、Q2 业绩同环比展望乐观的大储龙头：阳光电源。 风电：大金重工披露半年报业绩预告，Q2 业绩超预期，看好公司中长期盈利提升，继续坚定重点推荐；海南省发布 "136 号文"细则征求意见稿，增量海风项目获明显政策倾斜；浙江海风、日月、东缆等成立母港装备公司，关注浙 江深远海示范项目推进带来的订单机会。 电网：1）思源电气发布 25 中报业绩快报，25Q2 实现营收 53 亿元，同比+50%；归母净利润 8.5 亿元，同比+62%，大 超预期，上调公司 25 年盈利预测至 27.5 亿元，yoy+34%，当前股价对应 PE 仅 20 倍，维持重点推荐；2）国网输变电 设备 3 批中标金额 211.9 亿元，同比+38%，再创单批次中标金额新高，前 3 批累计中标同比+25 ...

医药生物 证券分析师 张静含 A0230522080004 zhangjh@swsresearch.com 李敏杰 A0230523070006 limj2@swsresearch.com 联系人 2025 年 07 月 13 日 本周医药上涨 1.8%，中方限制采 购欧盟医疗器械，默沙东百亿美元 获取 COPD 新药 看好 ——医药行业周报（2025/7/7-2025/7/11） 本期投资提示： 究 / 行 业 点 评 相关研究 《本周医药上涨 3.6%，创新药及高端器械 再迎支持政策，医保目录谈判正式启动， AZ/Summit 或达成超 150 亿美元交易 — —医药行业周报（2025/6/30- 2025/7/4）》 2025/07/06 《本周医药上涨 1.6%，医保目录调整将首 度纳入商保创新药目录，荣昌泰它西普完 成超 40 亿美元授权——医药行业周报 （2025/6/23-2025/6/27）》 2025/06/29 李敏杰 (8621)23297818× limj2@swsresearch.com 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 行 ...

Airbnb not only wants to rent you a vacation home this summer—it also wants to help you add a private chef or massage session. The hosts who own the condos, cottages and houses aren’t so sure. https://t.co/cCSVFOJ3yL ...

Core Viewpoint - Johnson & Johnson (JNJ) remains a strong long-term investment option despite facing legal challenges and potential revenue declines from patent expirations and price negotiations, supported by its innovative capabilities and diversified operations in healthcare [2][9][11]. Group 1: Company Performance and Innovation - Johnson & Johnson's shares have increased by 4,720% over the past few decades, highlighting its strong long-term performance [2]. - The company has successfully maintained a robust pharmaceutical segment, with over 10 medicines generating more than $1 billion in sales last year, showcasing its ability to innovate and replace older therapies [5][7]. - Johnson & Johnson has over 100 programs in its pipeline, indicating a commitment to future growth and the potential for new successful therapies [7]. Group 2: Diversification and Market Position - The company operates a well-diversified medtech business, marketing a range of medical devices across major therapeutic areas, which contributes to its leadership in the healthcare sector [8]. - Johnson & Johnson is developing the Ottava robotic-assisted surgery system, which presents long-term revenue opportunities and helps mitigate risks associated with patent cliffs [12]. Group 3: Financial Stability and Legal Challenges - Despite facing thousands of lawsuits related to its talc-based products, Johnson & Johnson is not at serious risk of bankruptcy, maintaining an AAA credit rating, which is higher than that of the U.S. government [10]. - The company has a strong history of dividend payments, having increased its payouts for 62 consecutive years, establishing itself as a Dividend King and appealing to income-oriented investors [13][14].

Core Viewpoint - The article discusses the rise of new ETFs introduced by BlackRock to provide investors with alternatives to traditional S&P 500 ETFs, addressing concerns over the heavy concentration of megacap stocks in the index [2][6]. Group 1: ETF Overview - The largest ETFs tracking the S&P 500 include the Vanguard S&P 500 ETF (VOO), SPDR S&P 500 ETF Trust (SPY), and iShares Core S&P 500 ETF (IVV) [1]. - BlackRock has launched the iShares S&P 500 3% Capped ETF and the iShares S&P 500 ex Top 100 ETF to allow investors to invest in the S&P 500 with reduced exposure to megacap stocks [3][4]. Group 2: ETF Features - The iShares S&P 500 3% Capped ETF limits each holding's weighting to a maximum of 3%, redistributing excess weight to companies below this cap [3]. - The iShares S&P 500 ex Top 100 ETF tracks the S&P 500 performance excluding the 100 largest stocks, allowing for a balanced exposure to megacap stocks [4]. Group 3: Performance and Costs - The iShares S&P 500 ex S&P 100 ETF has an expense ratio of 0.2%, while the iShares S&P 500 3% Capped ETF has a ratio of 0.15%, which can be reduced to 0.09% until April 2026 [7]. - In contrast, the Vanguard 500 S&P ETF has a much lower expense ratio of 0.03% and has shown strong long-term performance, with an average annualized return of 16.6% over the past five years [8]. Group 4: Market Dynamics - The S&P 500's performance is attributed to its market-cap-weighted structure, allowing successful companies to grow and dominate the index [9]. - A study by J.P. Morgan indicated that two-thirds of stocks in the Russell 3000 underperformed the index from 1980 to 2020, highlighting the importance of megacap stocks in driving market gains [10].

Core Viewpoint - The Vanguard Energy ETF is highlighted as a strong investment vehicle for generating dividend income, with the potential to create nearly $5,700 in annual dividends through consistent monthly investments over a long period of time [1][5]. Group 1: Investment Strategy - Investing $500 monthly in the Vanguard Energy ETF for 30 years can lead to a total investment of $180,000, assuming a consistent dividend yield of 3.16% [6][5]. - The ETF's current dividend yield of 3.16% is the highest among Vanguard's offerings focused on dividend income [3][4]. Group 2: ETF Composition - The Vanguard Energy ETF comprises 116 energy stocks, with major holdings in companies known for their dividends, such as ExxonMobil, Chevron, and ConocoPhillips [4][3]. - Energy stocks are characterized by their dividend payouts, making the Vanguard Energy ETF an attractive option for dividend-seeking investors [4]. Group 3: Dividend Growth Potential - Historical performance indicates that the Vanguard Energy ETF's dividend has more than quadrupled since its inception in 2004, despite a significant cut in 2015 [9]. - The ETF's current dividend level aligns with its average since launch, suggesting stability and potential for future increases [9]. Group 4: Reinvestment Benefits - Reinvesting dividends can significantly enhance total dividend income over time, potentially exceeding the projected $5,700 [8][11]. - The overall investment value could surpass the initial $180,000 if shares are sold periodically, further increasing total returns [11].

本文第一作者为香港科技大学（广州）机器人系一年级博士生宋文轩，主要研究方向为VLA模型，共同第一作者是来自香港科技大学广州的研究助理陈家毅，项 目leader为浙江大学和西湖大学联合培养博士生丁鹏翔，他们也是具身智能领域开源项目OpenHelix以及LLaVA-VLA的研究团队。通讯作者为香港科技大学广州 的李昊昂教授， 他是今年的CVPR2025 Best Paper Candidate的获得者。 针对这一问题，部分研究提出采用 Jacobi 解码替代传统的自回归解码，以期提升推理效率。然而，由于 Jacobi 解码往往需要较多迭代次数，其加速效果在实践中 较为有限。 为此，我们提出了一种 一致性蒸馏训练（consistency distillation training）策略 ，使模型在每次迭代中能够同时预测多个正确的动作 token，从而实现解码加速。 同时，我们设计了混合标签监督机制（mixed-label supervision），用于缓解蒸馏过程中可能产生的误差积累问题。 尽管上述方法带来了可接受的加速效果，我们进一步观察到：Jacobi 解码中仍存在若干低效迭代步骤，成为限制整体效率的关键瓶颈。 ...

证券研究报告 行业研究——周报 [Table_ReportType] [Table_StockAndRank] 石油加工行业 [Table_Author] 左前明 能源行业首席分析师 执业编号：S1500518070001 联系电话：010-83326712 邮箱：zuoqianming@cindasc.com 刘红光 石化行业联席首席分析师 执业编号：S1500525060002 邮箱：liuyilin@cindasc.com 刘奕麟 石化行业分析师 执业编号：S1500524040001 邮箱：liuyilin@cindasc.com 信达证券股份有限公司 CINDASECURITIESCO.，LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 大炼化周报：炼化产品价格价差仍 偏弱运行 [Table_ReportDate0] 2025 年 7 月 13 日 本期内容提要： [Table_Summary] ➢ 国内外重点炼化项目价差跟踪：截至 7 月 11 日当周，国内重点大炼 化项目价差为 2534.93 元/吨，环比变化-101.49 元/吨（-3. ...

For those of us that had no audience to get rich from bybit or other CEX reflinks in 2021+ mania, do we think Coinbase advanced (for perps/etc) will have reflinks for us to shill to our TradFi and stock maxi friends? ...